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Abstract
The mechanisms by which human immunodeficiency virus type 1 (HIV-1) crosses mucosal surfaces to establish infection are
unknown. Acidic genital secretions of HIV-1-infected women contain HIV-1 likely coated by antibody. We found that the
combination of acidic pH and Env-specific IgG, including that from cervicovaginal and seminal fluids of HIV-1-infected
individuals, augmented transcytosis across epithelial cells as much as 20-fold compared with Env-specific IgG at neutral pH
or non-specific IgG at either pH. Enhanced transcytosis was observed with clinical HIV-1 isolates, including transmitted/
founder strains, and was eliminated in Fc neonatal receptor (FcRn)-knockdown epithelial cells. Non-neutralizing antibodies
allowed similar or less transcytosis than neutralizing antibodies. However, the ratio of total:infectious virus was higher for
neutralizing antibodies, indicating that they allowed transcytosis while blocking infectivity of transcytosed virus.
Immunocytochemistry revealed abundant FcRn expression in columnar epithelia lining the human endocervix and penile
urethra. Acidity and Env-specific IgG enhance transcytosis of virus across epithelial cells via FcRn and could facilitate
translocation of virus to susceptible target cells following sexual exposure.
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Introduction
Sexual transmission of HIV-1 requires that virus establish
infection across genital tract or intestinal tissue. Sexually transmitted
infections, other causes of inflammation, and localized trauma may
allow susceptible CD4+ target cells at skin or mucosal surfaces to
become directly exposed to secretions from infected sexual partners
[1,2]. However, when skin andmucosa are intact, it remains unclear
precisely how HIV-1 gains access to target cells. One possibility is
that virus translocates between epithelial cells until susceptible cells
are found either in or below the epithelium [3]. Alternatively,
Langerhans cells may sample the surface, acquire virus, and move it
to areas of abundant target cells [4,5]. Finally, transcytosis of HIV-1
(i.e., movement through cells) has been studied as a potential
mechanism to translocate virus from mucosal surfaces to deeper-
lying CD4+ cells [6,7,8].
Transcytosis offers an explanation for movement of virus across
epithelial cells forming tight junctions, which might normally
exclude pathogens from moving beyond the surface. However, in
vitro, only a very small amount of virus, usually less than 0.3% of a
cell-free virus inoculum, finds its way through cells into the medium
bathing basolateral surfaces ([9]). Interactions between HIV-1 Env
and several host cell surface molecules, including glycolipids,
heparan sulfate proteoglycans and gp340, have been proposed to
play a role in transcytosis [10,11,12,13,14].
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With the exception of the acute phase prior to development of
anti-HIV-1 immune responses, semen, cervicovaginal, and rectal
fluids from HIV-1-infected individuals contain antibodies against
HIV-1 Env [15,16,17]. The concentration of Env-specific IgG
present in such secretions varies considerably from person to
person and is usually on the order of 100 to 1,000-fold less than
concentrations found in plasma [18]. The presence of Env-specific
IgG strongly suggests that some proportion of Env molecules on
the surface of infectious virions in genital tract secretions is coated
with IgG. Since HIV-1 is successfully transmitted sexually, the
coating antibody is either of insufficient quantity or quality to
neutralize virus infectivity upon contact with an uninfected
partner.
Antibody in genital tract secretions of HIV-1-infected individ-
uals could play a role in facilitating the transport of virus across
mucosal epithelia. Such a role is made particularly plausible by the
reported expression of the Fc neonatal receptor (FcRn) in human
genital mucosal tissue [19]. FcRn is a heterodimeric receptor
belonging to the MHC class I family of proteins [20,21]. The
expression of FcRn in endothelial cells is thought to be critical for
IgG homeostasis in blood [22], and its expression in placental
syncytiotrophoblasts is a key factor in transporting maternal IgG to
the fetal circulation [23]. A characteristic of FcRn is its ability to
bind the Fc region of IgG at acidic pH and to release it at neutral
pH [24]. This pH-dependent binding allows the transport of intact
IgG or of IgG immune complexes from luminal surfaces bathed in
acidic fluids, for example, cervicovaginal secretions, to basolateral
surfaces exposed to a neutral intracellular milieu [19].
Cervicovaginal secretions are maintained at acidic pH by acid-
producing bacteria that make up part of the normal vaginal
microbiota [25]. Although perturbations of normal microbiota,
such as occur with bacterial vaginosis, raise the pH, the secretions
generally remain in the acidic range [26,27]. Semen rapidly
neutralizes cervicovaginal secretions, but the extent of the pH
change is variable. For example, a large amount of ejaculate may
raise the pH to the neutral range, whereas a small amount may not
[28,29]. The pH of rectal secretions ranges from about 6.8 to 7.2
[30].
Given that HIV-1 in genital tract secretions may be complexed
with IgG antibody, that female genital tract secretions are acidic,
and that FcRn has been demonstrated in genital tract tissues, we
evaluated the role of pH and antibody on transcytosis of HIV-1
through polarized epithelial cells.
Results
Acidic pH and Env-specific IgG enhance transcytosis of
HIV-1
To investigate the effect of low pH and antibody on HIV-1
transcytosis across epithelial cells forming tight junctions, we
exposed the apical surface of HEC-1A cells to HIV-1 at pH 6.0 or
7.4 with or without HIV-1-specific IgG (HIVIG). Virus was
quantified in the medium bathing the basolateral cell surface
(‘‘subnatant fluid’’) by RT-PCR and, although detectable as early
as six hours after exposure of virus to the apical cell surface, the
quantity was greater at 12 hours (Figure S1) [8]. Thus, in
subsequent experiments, transcytosis was measured at 12 hours.
Using HIV-1US712, a clade B R5 clinical isolate, HIVIG enhanced
transcytosis in a dose-dependent manner when virus and antibody
were exposed to the apical surface at pH 6.0 (Figure 1A). There
was no increase in transcytosis with HIVIG at pH 7.4 or with
HIV-negative IgG (IVIG) at pH 6.0 or 7.4. We found similarly
enhanced transcytosis using additional R5 as well as X4 and X4/
R5 strains (Figure 1B). Importantly, transcytosis of four of five
clade C transmitted/founder Env-pseudotyped viruses was
enhanced in a pH and antibody-dependent manner (Figure 1C).
Enhanced transcytosis with HIV-1-specific antibody at low pH
also occurred with T84 colon carcinoma cells (Figure S2).
Since sexual transmission may occur with small amounts of
virus, we investigated if pH- and antibody-dependent enhance-
ment of transcytosis could occur at very low HIV-1 inocula. Using
HIVIG or the anti-gp41 monoclonal antibody (mAb) 2F5, we
found that transcytosis occurred with virus inocula as low as 2 pg
of p24 (about 60,000 RNA copies) with HIVIG and 0.02 pg of p24
(about 500 RNA copies) with 2F5, amounts too small to be
detectable in subnatant fluid in the absence of low pH and HIV-1-
specific antibody (Table 1). These quantities of virus are within
the range observed in seminal and cervicovaginal fluids of HIV-
infected individuals [31,32,33].
Enhanced transcytosis is mediated by FcRn
The impact of both antibody and low pH suggested FcRn
involvement [34,35]. We knocked down FcRn in HEC-1A cells,
verifying lower expression by flow cytometry and by Western blot
(Figure S3A). The knock-down HEC-1A cells attained the same
level of electrical resistance as did the wild-type cells (data not
shown), indicating that FcRn knockdown did not affect the ability
to form tight junctions. Unlike with wild-type HEC-1A cells, there
was no enhanced transcytosis with FcRn-knockdown HEC-1A
cells when either mAb 2F5 (Figure 2A) or polyclonal HIVIG
(data not shown) were used. We also evaluated Fc mutants of the
HIV-1 Env-specific mAb b12. A mutant designed to abrogate
FcRn binding (I253A), markedly lowered transcytosis compared
with wild-type b12 (Figure 2B) [36]. The second mutant
(M428L), designed to bind with higher affinity to FcRn, increased
transcytosis compared with wild-type b12 (Figure 2B) [37].
Binding to HIV-1JRFL gp120 (Figure S3B) and neutralization of
HIV-1JRFL (Figure S3C) were nearly equivalent for the wild-type
and Fc mutant versions of b12, indicating that the Fc mutations
did not affect Fab-antigen binding. Blockade of FcRn with
Author Summary
HIV-1 causes a sexually transmitted disease. However, the
mechanisms employed by the virus to cross genital tract
tissue and establish infection are uncertain. Since cervico-
vaginal fluid is acidic and HIV-1 in cervicovaginal fluid is
likely coated with antibodies, we explored the effect of low
pH and HIV-1-specific antibodies on transcytosis, the
movement of HIV-1 across tight-junctioned epithelial cells.
We found that the combination of HIV-1-specific antibod-
ies and low pH enhanced transcytosis as much as 20-fold.
Virus that underwent transcytosis under these conditions
was infectious, and infectivity was highly influenced by
whether or not the antibody neutralized the virus. We
observed enhanced transcytosis using antibody from
cervicovaginal and seminal fluids and using transmitted/
founder strains of HIV-1. We also found that the enhanced
transcytosis was due to the Fc neonatal receptor (FcRn),
which binds immune complexes at acidic pH and releases
them at neutral pH. Finally, staining of human tissue
revealed abundant FcRn expression on columnar epithelial
cells of penile urethra and endocervix. Our findings reveal
a novel mechanism wherein HIV-1 may facilitate its own
transmission by usurping the antibody response directed
against itself. These results have important implications for
HIV vaccine development and for understanding the
earliest events in HIV transmission.
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anti-FcRn antibody and inhibition of endosomal acidification by
bafilomycin A1 also substantially reduced or eliminated enhanced
transcytosis (Figure S3D–F), as did competition between the non-
HIV-1-specific mAb Den3 and the anti-HIV-1 Env mAb VRC01
(Figure S3G). Consistent with other investigations of Fc-FcRn
interactions, maximally enhanced transcytosis occurred at pH 5.5–
6.0, with some enhanced transcytosis apparent at pH 4.5 and 6.5
(Figure S3H) [38,39]. Since FcRn binds to IgG and not to IgA, we
compared two different IgG1 mAbs, b12 and HGN194, with their
IgA class-switched versions. Both IgG1 mAbs enhanced transcytosis
of HIV-1JRFL pseudoviruses and SHIV1157ipEL-p at pH 6.0, whereas
the IgA class-switched versions did not (Figure 2C and 2D). In
fact, as reported, dimeric IgA1 HGN194 inhibited transcytosis [40].
Thus, enhanced transcytosis at low pH in the presence of specific
antibody is mediated by IgG and is dependent on FcRn.
Using 50 mg/ml of VRC01 or Den3, transcytosis of IgG alone
increased approximately 3 fold from about 0.4% at pH 7.4 to
about 1.3% at pH 6.0 (Figure S4). However, the effect of FcRn-
mediated transcytosis on IgG alone does not appear as strong as
the effect on IgG immune complexes, where, for example, with
complexes made with 50 mg/ml of VRC01 or 2F5, there was
about an 8-fold increase in transcytosis under conditions allowing
FcRn engagement. This difference may be due to the contribution
of fluid phase uptake of IgG by the epithelial cells at both pH 6.0
and pH 7.4; IgG thus internalized can engage FcRn in acidic
endosomes and be shuttled to the basolateral side of the cells [41].
The internalization of immune complexes, on the other hand,
likely depends primarily on FcRn engagement at the surface of the
cell at pH 6.0.
Infectivity of transcytosed virus is affected by antibody
function
We evaluated the ability of HIVIG and a panel of mAbs
with variable neutralizing activities to mediate pH-dependent
Figure 1. HIV-specific IgG and low pH enhance HIV-1 transcytosis. (A) Indicated concentrations of HIV-specific IgG (HIVIG) or control IgG
(IVIG) and 2 ng of p24 (average of 3,814,910 RNA copies) of HIV-1US712 were added to the apical surface of HEC-1A cells at pH 6.0 or 7.4. Subnatant
fluid virus was quantified by RT-PCR and expressed as a percentage of inoculum applied to the apical surface of the HEC-1A cells. Data represent
mean+SE of eight independent experiments (some antibody concentrations were tested less frequently); p= 3.661028 comparing HIVIG at pH 6.0
with IVIG at pH 6.0; p= 3.461026 comparing HIVIG at pH 6.0 with HIVIG at pH 7.4 (Kruskal-Wallis test). (B) Enhanced transcytosis occurs with multiple
HIV-1 strains, including clade B R5 (HIV-1US657), R5/X4 (HIV-1HT593), and X4 (HIV-1HT599) strains. Data represent mean+SE of three independent
experiments for HIV-1US657 (average inoculum=1,096,491 RNA copies) and one experiment each for HIV-1HT593 (inoculum=2,450,255 RNA copies)
and HIV-1HT599 (inoculum=1,477,802 RNA copies). (C) IgG enhances transcytosis of clade C transmitted/founder Env-pseudotyped virus. IgG from
serum of clade C-infected or uninfected subjects was used at 50 mg/ml. Results are mean+SE of two independent experiments (average
inoculum=1,556,522 RNA copies) at pH 6.0 only; p=0.008 comparing clade C and HIV-Neg IgG (Kruskal-Wallis test).
doi:10.1371/journal.ppat.1003776.g001
Table 1. Enhancement of HIV-1 transcytosis occurs with low
viral inocula1.
Inoculum Subnatant Fluid (RNA copies)
p24 (pg) RNA copies No antibody HIVIG mAb 2F5
2000 64,295,720 250,028 886,060 3,782,575
200 7,949,017 29,223 116,640 362,063
20 652,246 1,983 10,328 34,765
2 62,343 neg 753 4,868
0.2 8,392 neg neg 658
0.02 523 neg neg 120
1Transcytosis carried out at pH 6.0 with 200 mg/ml of HIVIG or 100 mg/ml mAb
2F5; data are representative of three independent experiments.
doi:10.1371/journal.ppat.1003776.t001
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transcytosis with fully infectious HIV-1JRFL; 50% inhibitory
concentrations (IC50s) of the antibodies ranged from 0.06 to
.50 mg/ml (Fig. 3E). Both poorly neutralizing antibodies
(HIVIG and mAbs b6 and F240; Figure 3A) and neutralizing
mAbs (4E10, 2F5, 2G12, VRC01, and b12; Figure 3B) enhanced
transcytosis at pH 6.0. At 50 mg/ml, transcytosis correlated
directly with mAb binding to HIV-1JRFL (Spearman rho=0.75;
p=0.052) and inversely with the IC50 of the mAbs (Spearman
rho=20.71; p=0.050) (Figure S5). At pH 6.0, all Env-specific
mAbs and HIVIG mediated transcytosis of virus that infected
TZM-bl cells (Figure 3C and D). However, there was a strong
correlation between the amount of transcytosed infectious virus
and the neutralizing activity (IC50) of the antibody that mediated
the transcytosis (Spearman’s rho=0.86; p=0.001). Virus whose
transcytosis was mediated by poorly neutralizing antibodies
HIVIG, F240 and b6, at least at concentrations of 100 and
50 mg/ml, was more infectious than virus which crossed the
epithelial cells in a non-FcRn-dependent manner (i.e., in the
presence of Den3 control mAb) (Fig. 3C). Conversely, transcytosis
mediated by antibodies with the lowest IC50s, such as VRC01 and
b12, resulted in less infectious virus than was observed with the
Den3 control antibody (Figure 3D). Thus, strong binding activity
results in more FcRn-dependent transcytosis, whereas strong
neutralizing activity renders the transcytosed virus less infectious.
This point is further illustrated by the ratio of percent-
transcytosed:percent-infectious virus (Figure 3E). For example,
for every infectious unit, about 30 times more virus is transcytosed
with VRC01 than with HIVIG (Figure 3E). Note that
independently of transcytosis, HIV-1JRLF infectivity on TZM-bl
cells increased about 3.5-fold after incubation of virus for 12 hours
at pH 6.0 compared with pH 7.4; however, IC50s were very
similar (,15% difference) at the two pH values (pH comparisons
done for 2F5 and VRC01 only; data not shown). Virus infectivity
was essentially abrogated after a 12-hour incubation at pH 4.0
(data not shown).
IgG from genital tract secretions enhances transcytosis at
pH 6.0
We next determined whether IgG purified from cervicovaginal
fluid and from seminal fluid could enhance transcytosis at low pH.
Using IgG from cervicovaginal fluid of three HIV-infected women
and from seminal fluid of three infected men, enhanced
transcytosis occurred at IgG concentrations well within their
expected range in genital tract secretions (Figure 4A and 4B)
[18]. The ability of genital tract IgG to mediate transcytosis
correlated strongly with infectious virus capture activity by the IgG
(Spearman’s rho=0.94, p=0.005; Figure 4C) and less so with
binding to monomeric Env glycoprotein from the same virus strain
Figure 2. FcRn is responsible for pH/antibody-mediated enhanced transcytosis of HIV-1. (A) Knockdown of FcRn eliminates enhanced
transcytosis. Transcytosis was performed with the wild-type and FcRn knockdown HEC-1A cells in parallel at pH 6.0 or 7.4 using HIV-1US657 (average
inoculum=712,745 RNA copies) and mAb 2F5 or control mAb (Den3). Results represent mean+SE of three independent experiments; p=0.032
comparing wild type and knockdown cells using 2F5 at pH 6.0 (repeated-measures ANCOVA). (B) An Fc mutant of mAb b12 that increases FcRn
binding (M428L) increases transcytosis of HIV-1JRFL at pH 6.0, whereas a mutant that decreases FcRn binding (I253A) reduces transcytosis. Data
represent the mean+SE of two independent experiments. (C)(D) IgG1, but not IgA1 or IgA2, enhances transcytosis at pH 6.0. mAb IgG1 b12 or its
dimeric (dIgA2 b12) and monomeric (mIgA2 b12) class-switched versions and mAb IgG1 HGN194 or class switched variants dIgA1 HGN194 and dIgA2
HGN194 were tested for transcytosis using (B) HIV-1JRFL Env-pseudotyped virus (average inoculum=2,269,529 RNA copies) or (C) SHIV1157ipEL-p
(average inoculum=682,724 RNA copies). Fm-6 is an anti-SARS coronavirus IgG1 used as a negative control. All mAbs were tested at 50 mg/ml. Data
represent mean+SE of two independent assays for each virus. With either virus, IgG1 versions of the mAbs allow significantly more transcytosis at
pH 6.0 than do IgA versions combined (p=0.025 for HIV-1JRFL pseudoviruses and p= 0.021 for SHIV1157ipEL-p, Kruskal-Wallis test); there is no significant
difference between IgG and IgA versions at pH 7.4 (p.0.05).
doi:10.1371/journal.ppat.1003776.g002
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(HIV-1US657) (rho=0.65, p=0.16; Figure S6). None of the genital
tract IgGs were able to neutralize HIVUS657, the clinical R5 strain
used in these experiments, at IgG concentrations as high as 50 mg/
ml (not shown). Consistent with HIVIG and the non-neutralizing
mAbs, higher concentrations of genital tract IgGs generally
resulted in greater infectivity of the transcytosed virus
(Figure 4D and 4E).
FcRn is expressed in genital tract tissues
FcRn expression was previously reported in human uterine and
vaginal epithelial cells [19]. Using immunohistochemistry to
survey FcRn protein expression at various sites in the human
genital tract, we detected abundant FcRn expression in columnar
epithelial cells lining the human penile urethra (Figure 5A and
5D; Figure S7A and S7D) and endocervix (Figure 5B and 5E;
Figure S7B and S7E). In contrast, little to no FcRn protein was
observed in vaginal/ectocervical squamous epithelia, and expres-
sion occurred only in the basal epithelial layer (Figure 5C and
5F; Figure S7C). A similar staining pattern was observed in
foreskin tissue (data not shown).
Discussion
Female genital tract secretions are often acidic, and the
secretions of HIV-infected individuals have antibody capable of
coating virus contained in those secretions. These facts led us to
explore the role of antibody and low pH on transcytosis of HIV-1
across epithelial cells. Our primary finding is that at acidic pH, IgG
enhances transcytosis of HIV-1 clinical isolates, including transmit-
ted/founder Env-pseudotyped strains. Moreover, antibody from
Figure 3. Effect of antibodies on transcytosis and infectivity. Transcytosis (pH 6.0) of HIV-1JRFL by (A) poorly neutralizing HIVIG and mAbs b6
and F240 and (B) neutralizing mAbs 4E10, 2F5, 2G12, VRC01 and b12. HIV-1JRFL average inoculum=3,990,745 RNA copies. Dotted lines represent
mean+2 SD of % virus transcytosed with Den3 control mAb. There are significant differences between the Den3 control and 2F5 (p= 0.0002), b12
(p=0.007), 2G12 (p= 0.006), 4E10 (p= 0.001), b6 (p= 0.008), F240 (p= 0.002), and VRC01 (p=0.003) and between IVIG (not shown) and HIVIG
(p=0.033) (repeated-measures ANCOVA). (C) Infectivity of HIV-1JRFL whose transcytosis was mediated by poorly neutralizing or (D) neutralizing
antibodies. All antibodies resulted in transcytosed virus that was infectious (.mean+2 SDs of relative light units [RLUs] from uninfected TZM-bl cells
[dotted line]); average infectious inoculum=244,601 RLUs. Compared to Den3 control, less infectious virus was transcytosed with b12
(p=3.4610211), VRC01 (p= 6.9610210), and 2G12 (p=3.661024) (repeated-measures ANCOVA). Compared to Den3, there was more infectious virus
with F240 (p= 0.036) and with b6 (p= 0.068). Compared to IVIG (not shown), HIVIG resulted in more infectious virus (p=0.003). Data in A–D represent
mean+SE of three or four independent experiments. (E) Ratio of % transcytosed:% infectious virus from data in (A) and (B) using 50 mg/ml of
antibody. Numbers over bars represent IC50 against HIV-1JRFL.
doi:10.1371/journal.ppat.1003776.g003
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both cervicovaginal and seminal fluid mediates enhanced transcy-
tosis at low pH. The enhanced transcytosis is abrogated by blocking
or knocking down FcRn, which is known to bind IgG and immune
complexes at low pH and release them at neutral pH [24,42]. We
also establish that virus translocated across epithelial cells after
incubation with antibody at low pH remains infectious. Although
neutralizing antibodies generally promote more transcytosis, the
transcytosed virus is relatively less infectious than virus whose
transcytosis is mediated by non-neutralizing antibodies. Finally, we
demonstrate abundant FcRn protein expression in columnar
epithelial cells of the human endocervix and penile urethra,
suggesting that these sites could play a major role in FcRn-mediated
immune complex transcytosis.
Our results indicate that FcRn may be responsible for shuttling
IgG-bound HIV-1 across epithelial cells in the genital tract. This is
consistent with other studies that have highlighted a role for FcRn
in immune complex shuttling across tissues [34,35,43]. Mice
expressing human FcRn in intestinal epithelial cells were able to
deliver IgG to the luminal intestinal surface, which could then
bind to its cognate antigen and return the immune complex back
to the lamina propria for presentation by dendritic cells to CD4+
T cells [34]. In addition, cytomegalovirus (CMV) applied to
human placental explants from women with high anti-CMV
neutralizing antibody activity was rapidly transcytosed across
syncytiotrophoblasts and captured by villus macrophages [35].
Under these conditions, the virus did not replicate. However, in
Figure 4. IgG purified from genital tract secretions enhances transcytosis at pH 6.0. (A) Cervicovaginal (CVL) fluid IgG from three HIV-
infected women (CVL-A, CVL-B, and CVL-C) mediates enhanced transcytosis of HIV-1US657 (average inoculum=2,479,412 RNA copies) at pH 6.0. (B)
Similarly, IgG purified from seminal fluid of three HIV-infected men (SF-A, SF-B, and SF-C) enhances transcytosis of HIV-1US657 (average
inoculum=622,642 RNA copies) at pH 6.0. (C) Infectious HIV-1 capture by antibody in CVL and seminal fluids. Virus was captured by the indicated IgG
(5 mg/ml) and added to TZM-bl cells; infection was then quantified by RLUs. Infectious virus capture correlates with transcytosis at pH 6.0 (Spearman’s
rho= 0.94; p=0.005). Shown is the mean+SE of duplicate samples. The dotted line represents a negative cutoff based on the mean+2 SD of IgG from
cervicovaginal or seminal fluid of HIV-uninfected subjects. (D) (E) Both cervicovaginal fluid IgG (D) and seminal fluid IgG (E) mediate transcytosis of
infectious virus. Average infectious inoculum=1,160,894 and 1,913,288 relative light units [RLUs] for cervicovaginal and seminal fluid, respectively.
The dotted lines represent negative cutoffs based on the mean+2 SD of IgG from cervicovaginal and seminal fluid of the HIV-uninfected subjects.
Data shown (A, B, D, and E) are mean+SE of two independent assays.
doi:10.1371/journal.ppat.1003776.g004
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explants from CMV-seropositive women with low or undetectable
neutralizing antibodies, virus replication readily occurred in
cytotrophoblasts underlying an intact, uninfected syncytiotropho-
blast layer. Thus, it appeared that neutralizing antibody inhibited
infection after allowing virus to cross the syncytiotrophoblast layer.
On the other hand, non-neutralizing antibody allowed or even
promoted infection. Syncytiotrophoblasts express high levels of
FcRn, and when FcRn on explants was blocked, IgG-virion
complexes were not transported across the surface [35]. Just as we
found with HIV-1, FcRn-mediated transcytosis of CMV occurred
with both neutralizing and poorly neutralizing antibody, but
transcytosed virus remained infectious only when complexed with
poorly neutralizing antibody. Finally, immunohistochemical
staining of placentas from in utero infections were consistent with
this model of FcRn-mediated transcytosis [35].
To our knowledge, ours is the first study to investigate
transcytosis using virus coated with HIV-specific antibody in an
acidic environment that mimics that of the female genital tract. Our
in vitro observations are applicable to male-to-female transmission
via vaginal intercourse, where enhanced transcytosis could facilitate
infection. In this regard, Li et al. reported FcRn expression and
bidirectional IgG transport in a human vaginal tissue model [19].
Although we did not detect FcRn in the apical layers of vaginal
epithelium, we did detect abundant FcRn expression in columnar
endocervical epithelial cells. These cells may be exposed to acidic
vaginal secretions where they occur at the cervical os. Furthermore,
cervical ectopy, a common condition characterized by the extension
of endocervical columnar epithelium into the ectocervix and upper
vagina, has been implicated as a risk factor for HIV-1 infection
[44,45]. Prevalent in reproductive-age women, these cervical lesions
are exposed to vaginal pH conditions and could provide portals for
FcRn-mediated male-to-female HIV-1 transmission [46]. FcRn was
also found, though not consistently, in basal epithelial cells of the
vagina. These cells lie deep in the epithelium and are unlikely to
come in contact with acidic secretions and HIV-1 immune
complexes unless there were trauma or substantial thinning of the
overlying squamous epithelium. It is important to note that seminal
fluid can rapidly raise the pH of cervicovaginal secretions to levels
which would not support immune complex-FcRn binding. How-
ever, the pH of cervicovaginal fluid following ejaculation is
dependent on the quantity of the ejaculate and may stay within
an acidic range [29]. Furthermore, HIV is present in preejaculate
secretions and could be introduced into the female genital tract
prior to ejaculation [47].
With respect to female-to-male transmission, the penis comes in
contact with vaginal secretions that would remain at acidic pH at
least until ejaculation, allowing time for exposure of penile tissues,
including the foreskin and urethra, to IgG-coated virus at low pH
[28,29]. Our demonstration of abundant FcRn on human penile
urethral epithelium supports a model where exposure to antibody-
bound HIV-1 might lead to enhanced female-to-male transmis-
sion. It should be noted that the pH of vaginal secretions is
typically about 4, which is below the pH required for Fc-FcRn
binding [48]. However, there is substantial variability in normal
vaginal pH [26,48], and we did begin to observe enhanced
transcytosis at pH 4.5 (Figure S3H). Furthermore, it is possible
that there is some buffering effect of foreskin and urethral
secretions. The foreskin, whose presence increases HIV infection
rate, could trap secretions containing HIV-1 immune complexes
and thereby allow greater urethral exposure to infected material
Figure 5. FcRn expression in human genital tissues, detected by immunohistochemistry. FcRn expression (red stain) in columnar epithelia
lining (A) the penile urethra (representative of 16 donors), (B) endocervix (representative of five donors), or (C) vagina (representative of 12 donors).
Tissues were also stained with negative control (non-specific) IgG and processed through the same immunohistochemistry procedure: (D) penile
urethra, (E) endocervix, and (F) vaginal epithelia. Epithelia (EP) and lamina propria (LP) are labeled. Staining was performed on paraffin-embedded
specimens.
doi:10.1371/journal.ppat.1003776.g005
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within the pH range of Fc-FcRn binding [49]. Additionally,
bacterial vaginosis, a condition associated with an increased risk of
female-to-male (as well as male-female) HIV transmission, results
in vaginal secretions ideal for Fc-FcRn binding [26,27,50].
Exposure of penile tissues to the pH range of Fc-FcRn binding
may also occur after ejaculation, since complete neutralization of
vaginal acidity may not occur immediately or at all [29]. It is also
possible, though less likely, that FcRn mediates HIV transmission
via the penis during insertive anal intercourse, where the penis
may come into contact with slightly acidic rectal secretions [30].
The finding that IgG from cervicovaginal and seminal fluids
obtained from HIV-infected individuals mediate enhanced
transcytosis of infectious virus further suggests the biological
relevance of our results. Cervicovaginal and seminal fluids are
reported to contain an average of ,3 mg/ml and up to ,15 mg/
ml of Env-specific IgG [18]. Four of the six samples we evaluated
bound to infectious HIV-1 at 5 mg/ml. Moreover, all of our
samples mediated transcytosis at #12.5 mg/ml of total IgG, well
below total IgG concentrations found in genital secretions of HIV-
infected men and women [18]. Even during acute HIV infection,
when the risk of transmission to an uninfected partner is highest,
23 of 23 subjects (100%) were reported to have anti-gp41 IgG
antibodies and 40% had anti-gp120 IgG antibodies in cervico-
vaginal and seminal fluids [17]. Anti-gp41 IgG levels were on
average 11-fold higher than gp41-specific IgA levels; anti-gp41
IgM was found less frequently and in lower quantity. Thus, HIV-1
immune complexes are likely to occur in mucosal secretions, are
likely to contain predominantly IgG, and under acidic conditions,
would be subject to FcRn-mediated transcytosis in an exposed
host.
The relevance of our findings is also supported by our
demonstration that transcytosis of transmitted/founder strains of
HIV-1 Env pseudotyped virus is enhanced by antibody. We are
currently evaluating whether transmitted/founder strains, in
comparison with chronic strains, are preferentially transcytosed,
which would be consistent with a report showing a higher
sensitivity of clade B transmitted/founder strains to anti-Env
antibody binding [51].
Our findings represent a new model of antibody-dependent
enhancement (ADE) of HIV-1 infection. Previous studies have
demonstrated ADE in vitro due to FccR- or complement-mediated
mechanisms or to modulation of the interaction of gp120 with
CCR5 [52,53,54]. Here we demonstrate that enhancement in vitro
occurs at the level of transcytosis across epithelial cells and involves
FcRn. In vivo, Ig isotype, as well as neutralizing activity, are likely
to play a determining role in whether an antibody might protect
from or enhance infection. As demonstrated recently, intrarectally
applied dIgA1 HGN194 mAb, but less so the IgG1 version,
prevented SHIV infection following intrarectal challenge [40]. In
vitro, the dIgA1 inhibited transcytosis, whereas we now show that
the IgG1 version enhances transcytosis at pH 6.0. Another study
showed that, compared to irrelevant- and no-antibody controls,
there was an increase in the number of transmitted/founder SHIV
variants when vaginal challenge followed systemic or local infusion
of a non-neutralizing IgG1 mAb [55]. Clearly, other studies have
found that IgG with neutralizing activity can prevent lentivirus
infection after vaginal challenge [56,57]. Thus, whereas a strong
vaccine-induced neutralizing IgG response may protect, non-
neutralizing IgG or waning titers of neutralizing IgG present in an
acidic lumen might enhance transcytosis across mucosal barriers
while allowing infection of susceptible target cells. However,
whether an antibody protects, enhances or has no effect is likely to
depend on the potency and breadth of antiviral activity, the viral
strain, the inflammatory state of the exposed individual, and
genetic factors—such as FccR polymorphisms—that might
influence antibody function [58]. Finally, if FcRn-mediated
transcytosis applies in vivo, our results would strengthen the
argument for a mucosal IgA response to vaccination—though not
at the exclusion of a strong IgG neutralizing or other anti-viral
response—since IgA can inhibit transcytosis, would not engage
FcRn, and mediates only uni-directional translocation of immune
complexes from the subepithelial space into external secretions
[40,59].
Some studies have reported that anti-HIV-1 Env IgG antibodies
can inhibit transcytosis [9,60,61]. One of these studies found that
polyclonal anti-HIV Env IgG inhibited transcytosis of cell-free
virus on HEC-1 cells, whereas none of 13 mAbs did; in fact, some
of the mAbs might have increased transcytosis, although by no
more than about 50% [61]. To our knowledge, none of these
studies was carried out under the acidic conditions that
characterize female genital tract secretions.
Our results suggest that FcRn might facilitate infection in hosts
without pre-existing antibody or with a non-neutralizing IgG
response to prior infection (which would result in secondary
infection) or to vaccination. However, FcRn could also play a
beneficial role in preventing infection after exposure. FcRn
mediates the bidirectional transcytosis of IgG, and in immunized
individuals, could provide a conduit for antibodies to neutralize
virus as shown for herpes simplex virus type 2 [19]. In addition,
IgG immune complexes can prime CD4+ and CD8+ T cells in an
FcRn-dependent manner, and FcRn targeting may be a useful
mucosal immunization strategy [62,63,64].
In summary, we have demonstrated that FcRn mediates
enhanced transcytosis of HIV-1 in the presence of low pH and
HIV-1-specific antibody. We have also shown that FcRn is present
on epithelial cells in areas of the genital tract that are potentially
exposed to HIV-1 during sexual intercourse. Our findings point
toward a novel mechanism by which the sexual transmission of
HIV-1 may be facilitated.
Methods
Ethics statement
This research was approved by the Institutional Review Boards
at the University of California, Irvine, Boston University, and the
University of Alabama, Birmingham. Subjects from whom
specimens were collected for study purposes provided written
informed consent.
Cell lines, cell culture media, and viruses
Human Endometrial Carcinoma (HEC-1A) cells (ATCC) were
propagated in Modified McCoy’s 5a Medium, and Human Colon
Carcinoma (T84) cells (ATCC) in Dulbecco’s modified Eagle’s
medium; media were supplemented with 2.5 mM L-glutamine
(Gibco, Invitrogen Technologies), 1% Penstrep (Cellgro Media-
tech Inc.) and 10% FBS (Atlas Biologicals) and maintained at 37uC
with 5% CO2. TZM-bl cells (NIH AIDS Reagent Program) for
infectivity assays were propagated in RPMI 1640 supplemented
with L-glutamine, Penstrep and 10% FBS as above. Five primary
clinical HIV-1 strains, HIV-1US657, HIV-1US712, HIV-1JRFL,
HIV-1HT593, and HIV-1HT599 were obtained from the NIH AIDS
Reagent Program. SHIV1157ipEL-p, provided by Ruth Ruprecht,
was grown in rhesus peripheral blood mononuclear cells [65].
Antibodies
HIVIG (IgG derived from pooled plasma of HIV-infected
individuals) and IgG1 monoclonal antibodies (mAbs) 2F5, 4E10,
2G12, F240, b6, and VRC01 were obtained from the NIH AIDS
FcRn Mediates Enhanced Transcytosis of HIV-1
PLOS Pathogens | www.plospathogens.org 8 November 2013 | Volume 9 | Issue 11 | e1003776
Reagents Program. IVIG (Gamunex, Taleris Biotherapeutics) was
commercially acquired. mAb b12 and control mAb Den3 were
provided by Dennis Burton and Brian Moldt, and control mAb
Fm-6 was a gift of Wayne Marasco (Dana-Farber Cancer
Institute); b12 and the control mAbs are IgG1. Generation and
purification of dimeric and monomeric IgA2 versions of b12
(dIgA2 b12 and mIgA2 b12) are described elsewhere [66]. Briefly,
the IgG constant region in pDR.12 (IgG b12) was replaced with
the constant region of IgA2. IgA2 b12 was expressed in CHO-K1
cells with human J chain and purified by Protein L affinity matrix
(Pierce). mIgA b12 and dIgA b12 were isolated by size exclusion
chromatography. IgG1 HGN194 (a human mAb against HIV-1
Env V3), dIgA1 HGN194, and dIgA2HGN194 were provided by
Davide Corti and Antonio Lanzavecchia [67]. HGN194 variants
were constructed as follows: human J chain precursor (accession
number NP_653247), IgA1 (allele IGHA1*01, accession number
J00220) and IgA2 (allele IGHA2*01, accession number J00221)
constant region nucleotide sequences were codon optimized and
synthesized by Genscript. Constant regions were cloned into a
mammalian expression vector used for subcloning of the HGN194
VH region. The HGN194 VH and VL chain were codon
optimized and synthesized by Genscript and cloned into an IgG1
and Ig-lambda expression vector. MAbs HGN194 dIgA1, dIgA2,
and IgG1 were produced by transient transfection of 293 freestyle
cells with polyethylenimine and expression plasmids encoding
corresponding heavy and light chains (in the case of dIgA1 and
dIgA2, the J chain expression plasmid was included). Supernatant
fluid from transfected cells was collected after 7–10 days of culture.
HGN194 dIgA1, dIgA2, and IgG1 were affinity purified by
Peptide M (dIgA1 and dIgA2) or Protein A (IgG1) chromatogra-
phy. Purified Abs were quantified by ELISA using dIgA1 and
dIgA2 or IgG1-specific Abs (Southern Biotech). Purity and
polymeric state of dIgA1 and dIgA2 were confirmed by native-
PAGE analysis and gel filtration chromatography. The presence of
dIgA1 and dIgA2 associated J-chain was confirmed by Western
blot from native and SDS-PAGE gels. Sera from 20 Zambian
clade C-infected subjects (obtained from Zdenek Hel, University of
Alabama, Birmingham) were pooled for IgG isolation using the
Pierce Melon Gel IgG Spin Purification Kit (Thermo Scientific)
according to the manufacturer’s instructions. Env-specific IgG,
determined as for CVL and seminal fluid (see below), was 0.98%
of total IgG. Sera from five uninfected individuals were pooled and
processed for IgG isolation in the same manner.
Fc mutants designed to enhance (M428L) or reduce (I253A)
mAb b12 binding to FcRn were constructed as follows: briefly, the
b12 variable regions were PCR-amplified from pDR12 and cloned
into the pc1HC and pkLC vectors [68,69]. Amino acid
substitutions were introduced by QuikChange site-directed muta-
genesis (Stratagene, La Jolla, CA). Constructs were verified by
sequence analysis before transiently expressed in FreeStyle 293
cells (Invitrogen, Carlsbad, CA) and purified by protein A affinity
chromatography (GE Healthcare, United Kingdom).
Virus neutralization assay
Antibodies were tested for neutralizing activity against indicated
HIV-1 strains using TZM-bl cells.
Virus capture assay
Half-area 96-well plates (Corning) were coated with 5 mg/ml
(250 ng/well) of goat anti-human Fc antibody and incubated over
night at 4uC. Plates were then washed with PBS and blocked with
4% non-fat dry milk for 1 hour at room temperature (RT). After
washing, capture antibodies were added at 5 mg/ml (250 ng/well),
and plates were incubated an additional hour at RT. Next, virus
was added to washed plates (20 ng p24/well) and incubated for
3 hours at 37uC. Unbound virus was removed by washing with
PBS. Subsequently, 16104 TZM-bl cells/well were added in the
presence of 10 mg/ml DEAE dextran and incubated for 48 hours
at 37uC. Cells were then washed, lysed, and developed with
luciferase assay reagent according to the manufacturer’s instruc-
tions (Promega). Luminescence (relative light units) was measured
using a Synergy 2 microplate luminometer (BioTek).
Antibody binding assays
We measured binding of antibodies either to virus directly
coated on ELISA-plate wells or to solubilized Env. For the direct
virus binding assay, plates were coated with HIV-1JR-FL (20 ng
p24/well) for 2 hours at 37uC, washed with PBS and blocked with
4% non-fat dry milk in PBS. After 1 hour at 37uC, plates were
washed, antibodies were added in serial dilutions and incubated
for 1 hour at 37uC. Detector antibody (horse radish peroxidase-
labeled goat anti-human Fc) was added to the washed plate and
incubated for 45 min at 37uC. Finally, plates were washed,
developed (TMB solution, Life Technologies), and read at 450 nm
using a plate reader (BioTek).
The soluble Env binding assay was performed as previously
described with some modifications [70]. Briefly, wells were coated
with 250 ng of a gp120 Env specific anti-C5-antibody (D7324
[Aalto Bioscience]), washed and blocked with 4% non-fat dry milk.
Serial dilutions of detergent-solubilized HIV-1JR-FL (starting at
150 ng p24) was added and incubated for 2 hours at 37uC. Plates
were then incubated with a constant concentration of antibodies
(1 mg/mL) for 1 hour at 37uC followed by detection and
development steps as described above.
Clade C transmitted/founder Env pseudotyped virus
Five R5 clade C transmitted/founder Env pseudotyped strains
were constructed as described [71,72]. Briefly, rev-vpu-env
cassettes from the transmitted founder strains were cloned into
pcDNA 3.1D/V5-HIS TOPOH expression vector. The pseudo-
typed viruses were then produced by co-transfecting 293T cells
with pcDNA 3.1(rev-vpu-env), pNL4-3.lucR-E-, and fugene 6
(Roche).
Cervicovaginal and seminal fluid IgG
Cervicovaginal lavage (CVL) and seminal fluid were collected
from HIV-1-infected patients and healthy volunteers at the
University of Alabama, Birmingham. All subjects gave written
consent in accordance with an IRB-approved protocol. CVL was
collected from one 34 year-old uninfected women and from three
infected women (age 29 to 46 years) with CD4+ lymphocyte
counts of 458/mm3, 181/mm3 and 498/mm3 and plasma viral
loads of 14100 copies/ml, 824 copies/ml and 88 copies/ml,
respectively. Viral loads were not measured in the CVL fluid
specimens. Two of the women (with the lower plasma viral loads)
were receiving anti-retroviral therapy. Briefly, CVL fluid was
obtained by flushing the cervix and vagina with 5 ml sterile saline,
and the wash was collected into tubes with protease inhibitors
([73]). Seminal fluid was obtained from two uninfected men (ages
25 and 40 years), and from three infected men (age 43 to 53 years)
by masturbation (58). CD4 counts in the infected men were 404/
mm3, 336/mm3 and 407/mm3 and plasma viral loads were ,100
copies/ml, 8092 copies/ml and 6750 copies/ml, respectively; only
one of these subjects (with viral load of 11 copies/ml) was receiving
anti-retroviral therapy. Seminal fluid was assayed for HIV-1 RNA
by PCR, but none was detected. The cervicovaginal and seminal
fluids were centrifuged and supernatant fluids aliquoted and frozen
at 280uC until assayed. Total IgG was determined by ELISA
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[74]. IgG isolation was accomplished by incubating samples with
Protein G-Sepharose (GE Healthcare Bio-Sciences Corp.) fol-
lowed by elution of bound IgG according to manufacturer’s
instructions. The IgG preparations were concentrated and
dialyzed against DPBS using Amicon Centrifugal Filter Units
(Millipore Corp.). The IgG preparations from the two uninfected
men were pooled to obtain sufficient quantity for experiments; all
other IgG preparations were tested individually.
Env-specific IgG binding levels in seminal and CVL fluids were
quantified by ELISA. Detergent-solubilized Env from HIV-1US657
was captured by a polyclonal sheep anti-gp120 antibody (D7324,
Aalto Bio Reagents Ltd). Sample IgG and an anti-gp120 mAb
standard (b6) were serially diluted, added to wells, washed, and
detected by anti-human IgG (gamma)-HRP (Sigma-Aldrich, A6029)
antibody. Plates were subsequently developed, stopped, and read at
OD450 nm. The concentrations of Env-specific IgG in the seminal
and CVL IgG samples were calculated using the mAb b6 standard
and are reported as a percent of total IgG in each sample.
Anti-Env IgG ranged from 0.9 to 2.6% of total IgG in the
seminal fluid specimens and from 0.1 to 0.6% of total IgG in the
CVL fluids specimens (Figure S6).
Dual chamber transcytosis assay
Transcytosis assays were conducted using reproductive tract-
derived (human endometrial carcinoma [HEC-1A]) or intestinal
tract-derived (human colonic carcinoma [T84]) cells. HEC1-1A or
T84 cell monolayers were created on 0.4 mm polyethylene
terephthalate membrane hanging transwell inserts (Millipore).
Cell viability was.95% at the time of plating. Electrical resistance
across the membrane, which ranged from 400–450 mOhms/cm2
at the start of the transcytosis assay, confirmed monolayer
integrity. Resistance was re-measured after the transcytosis assay
in more than 50% of wells and ranged from 450–480 mOhms/
cm2. HIV-1 alone or with antibody was added to monolayers in
media buffered to pH 6.0 or 7.4. After 12 hours, fluid in the lower
chamber (‘‘subnatant fluid’’), maintained at pH 7.4, was collected
and used to measure viral RNA copy number and infectivity. In
the absence of cell monolayers, about 69% of the virus inoculum
was present in the lower chamber of the wells after 12 hours.
Viral RNA extraction and quantitative RT-PCR
Viral RNA was extracted from cell-free subnatant fluid using
PureLink Viral RNA Mini Kits (Invitrogen) or NucleoSpin RNA
Virus extraction kits (Macherey Nagel Inc.), according to the
manufacturers’ instructions. Quantitative one-step real-time RT-
PCR of extracted HIV-1 viral RNA was done using Quantitect
SYBR Green RT-PCR kits (Qiagen GmbH) and that of
SHIV1157ipEL-p with Rotor Gene Probe RT-PCR kits according
to the manufacturers’ instructions. HIV-1gag primers: SK462
d(AGTTGGAGGA-CATCAAGCAGCCATGCAAAT) and SK431
d(TGCTATGTCAGTTCCCCTTGGTTCTCT) (AnaSpec Inc.).
SIV-1 gag primers: d(GGG AGA TGG GCG TGA GAA A) and
d(CGT TGG GTC GTA GCC TAA TTT T). SIV-1 gag probe:
d(TCA TCT GCT TTC TTC CCT GAC AAG ACG GA)
(Integrated DNA Technologies, Inc.).
Infectivity assays
150 ml of subnatant fluid was used to infect 16104 TZM-bl cells.
TZM-bl cells were lysed 2 days post-infection with 1X Cell
Culture Lysis Reagent (Promega Corp.), and luciferase activity was
determined by chemiluminescence using Luciferase Substrate
(Promega Corp.).
FcRn knockdown of HEC-1A cells
HEC-1A cells were transduced with FcRn shRNA Lentiviral
Particles (Santa Cruz Biotechnology Inc.) following manufacturer’s
protocol. Cells were selected in medium containing 5 mg/ml
Puromycin dihydrochloride (Sigma-Aldrich Inc.), and FcRn
expression was verified by flow cytometry using rabbit polyclonal
anti-FcRn antibody (Santa Cruz Biotechnology Inc.), normal
rabbit IgG (negative control) and FITC-goat anti-rabbit IgG
F(ab9)2 secondary antibody (Jackson ImmunoResearch Laborato-
ries Inc.) (Figure S3A). Cytofix/Cytoperm Plus Kits (BD
Biosciences) were used to fix, permeabilize and stain cells.
Knockdown of FcRn was also confirmed by western blot using
rabbit anti-FcRn antibody (Novus Biologicals) (Figure S3A).
Wild-type and knockdown cells had similar viability. Neither wild-
type nor knockdown HEC-1A cells stained for FccRIIa or
FccRIIIa (not shown).
FcRn blocking and inhibition of endosomal acidification
HEC-1A cells were incubated with 50 mg/ml rabbit polyclonal
anti-FcRn IgG (H-274; Santa Cruz Biotechnology Inc.) or normal
rabbit polyclonal IgG for 1 hour at pH 7.4 before exposing the
apical surface to HIV-1US712 and HIVIG, b12, IVIG or Synagis.
Similarly, HEC-1A cells were incubated with 0.1 mM bafilomycin
A1 (Santa Cruz Biotechnology Inc.) for 1 hour prior to HIV-1 and
antibody exposure. Transcytosis was then carried out as above.
Detection of FcRn protein expression in human genital
tissues by immunohistochemistry
Cervical tissue, which included portions of endocervix and
upper vagina (ectocervix), was obtained from 10 women aged 31–
50 undergoing hysterectomy for nonmalignant conditions. Vaginal
tissue was also obtained from women undergoing vaginal repair
(n = 6, aged 44–78 years). Penile tissue, including urethra (n = 16)
and foreskin (n = 2), was harvested at autopsy from 16 men aged
34–73 with no history of hormonal or immunosuppressive
medications. Tissues were processed within 60 minutes of surgical
removal. Samples were either embedded in Tissue-Tek Optimal
Cutting Temperature Compound (Sakura Finetek U.S.A., Inc.)
and rapidly frozen and stored at 270uC (frozen sections) or were
fixed in formaldehyde and processed for paraffin embedding.
The alkaline phosphatase immunohistology technique was
described previously ([75]). Two anti-FcRn antibodies were used:
1) Anti-FcRn antibody purified from rabbit serum raised against
a2 (88–177aa) and a3 (1782-247aa) domains of human FcRn
(provided by Neil Simister, Brandeis University) for use on frozen
sections (Figure 5), and 2) rabbit anti-FcRn antibody obtained
from Novus Biologicals for use on paraffin sections following
citrate buffer (pH 6.0) antigen retrieval (Figure S7). Sections were
blocked with serum-free protein solution, and optimally diluted
primary FcRn antibodies or rabbit IgG (negative control) were
added and incubated for 1–2 hours at RT. Binding of antibodies
to FcRn in tissues was visualized using an alkaline phosphatase
detection system that stains positive cells bright red. Sections were
counterstained with hematoxylin and cover-slipped using aqueous
mounting medium.
Statistics
Differences in amounts of transcytosed or infectious virus
between conditions were compared using Kruskal-Wallis or
repeated-measures ANCOVA. For repeated-measures ANCOVA,
the percentage of transcytosed or infectious virus was logit-
transformed and normality evaluated using the Shapiro–Wilk test.
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Correlations between continuous variables were evaluated by
Spearman’s rho. Two-tailed p-values are reported.
Supporting Information
Figure S1 Transcytosis of HIV-1 at pH 6.0 over time. HIV-
1JRFL with HIVIG, IVIG or no antibody was applied to the apical
surface of HEC-1A cells at pH 6.0. At the indicated times,
subnatant fluid (pH 7.4) was collected, and transcytosis was
quantified by RT-PCR.
(PPTX)
Figure S2 Antibody and low pH-mediate enhanced transcytosis
of HIV-1 across T84 colonic carcinoma cells. HIV-1US657 and the
indicated concentrations of HIV-specific IgG (HIVIG) or control
IgG (IVIG) were applied to the apical surface of T84 colonic
carcinoma cells at pH 6.0 or 7.4. After 12 hours, virus in the
subnatant fluid was quantified by RT-PCR and expressed as a
percentage of the inoculum added to the apical surface. Data
represent the mean+SE of two independent experiments. Similar
results were obtained in an additional experiment using another
R5 strain of HIV-1 (HIV-1US712).
(PPTX)
Figure S3 Enhanced transcytosis is due to FcRn. (A) Knock-
down of HEC-1A cells was accomplished using lentivirus particles
expressing small hairpin RNA and verified by flow cytometry (left
panel) and Western blot (right panel) using rabbit polyclonal anti-
FcRn antibodies; WT=wild-type HEC-1A cells and KD=FcRn-
knockdown HEC-1A cells. GAPDH was used as a protein-loading
control. (B) Binding of wild-type mAb b12 and Fc mutants of b12
(M428L and I253A) to HIV-1JRFL gp120 by ELISA is equivalent. (c)
Neutralization of HIV-1JRFL by wild-type b12 and its Fc mutants are
similar. IC50 values for wild-type b12, M428L, and I253A are 0.03,
0.04, and 0.02 mg/ml, respectively. (D–F) Enhanced transcytosis of
HIV-1 is blocked by bafilomycin A1 and by an anti-FcRn antibody.
HIVIG and HIVUS657 (D) or HIVIG or mAb b12 and HIVUS712 (E,
F) were added to the apical surface of HEC-1A cells at pH 6.0 in the
presence or absence of 0.1 mM bafilomycin A1 (D–F) or in the
presence of rabbit polyclonal anti-FcRn IgG (50 mg/ml) or normal
rabbit polyclonal IgG (‘‘Neg antibody’’) (E, F). Data represent mean
+ SE of two independent experiments (D) or single experiments (E,
F). (G) Non-HIV-specific mAb (Den3) inhibits VRC01-mediated
enhancement of transcytosis of HIV-1 at pH 6.0. Immune
complexes, made with 25 mg/ml of VRC01 and HIV-1JRFL, were
added to the apical surface of HEC-1A cells in the presence of
indicated concentrations of Den3 at pH 6.0. Subnatant fluid
(pH 7.4) was collected 12 hours later, and virus was quantified by
RT-PCR. Numbers above the bars indicate the % inhibition of
transcytosis. Data represent mean + SE of two independent
experiments. (H) Maximum transcytosis in the presence of HIV-1-
specific antibody occurs at pH 5.5–6.0. HIV-1JRFL was incubated
with HIVIG (50 mg/ml) at indicated pH values and added to the
apical surface of HEC-1A cells. Transcytosis was quantified by RT-
PCR in subnatant fluid collected 6- and 12-hours later. Note that
IVIG and no antibody controls, used at pH 6.0 only, gave similarly
low levels of transcytosis compared to HIVIG at pH 7.4 (not shown).
(PPTX)
Figure S4 Transcytosis of IgG alone is influenced by pH at the
apical cell surface. 50 mg/ml of mAbs Den3 or VRC01 were
added to the apical side of HEC-1A cells. Twelve hours later, IgG
was quantified in the subnatant fluid by ELISA.
(PPTX)
Figure S5 Transcytosis of HIV-1JRFL correlates directly with
mAb binding and inversely with neutralizing activity. (A) mAb
binding by ELISA to HIV-1JRFL directly coated on plates. (B)
Correlation between mAb binding and transcytosis at 50 mg/ml of
mAb (Spearman rho=0.75; p=0.052). (C) Correlation between
IC50 (see Figure 3E) and transcytosis at 50 mg/ml of mAb
(Spearman rho=20.71; p=0.050).
(PPTX)
Figure S6 Anti-monomeric Env binding activity of CVL and
seminal fluid IgG as a percentage of total IgG. The dotted line
represents a negative cutoff based on the mean+2 SD of IgG from
cervicovaginal and seminal fluid of the HIV-uninfected subjects.
Shown is the mean+SE of two independent assays, each done in
duplicate.
(PPTX)
Figure S7 Additional examples of FcRn expression in the
columnar epithelia of human penile urethra and endocervix. (A)
Penile, (B) endocervical or (C) vaginal tissue was stained with
affinity-purified anti-human-FcRn rabbit IgG or with normal
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